Under Steve’s leadership, Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades.
In addition, Steve discovered Pulmozyme® (dornase alfa), a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis.